Mainz BioMed N.V. | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55332	Articles
62460	Press releases

Home
Companies
Mainz BioMed N.V.

BRIEF

published on 09/04/2024 at 10:06, 2 months 17 days ago

Mainz Biomed Partners with Liquid Biosciences to Enhance Pancreatic Cancer Detection

AI Mainz Biomed Biomarkers Liquid Biosciences PancAlert
PRESS RELEASE

published on 09/04/2024 at 10:01, 2 months 17 days ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Mainz Biomed partners with Liquid Biosciences to leverage AI for biomarker selection in PancAlert, a next-gen pancreatic cancer detection test. Companies expand collaboration with promising results and plan to complete analysis by Q4 2024

AI Mainz Biomed Liquid Biosciences PancAlert Biomarker Selection
BRIEF

published on 07/25/2024 at 14:06, 3 months 26 days ago

Mainz Biomed Launches Enhanced ColoAlert to Improve Screening Efficiency

ColoAlert Mainz Biomed Colorectal Cancer Screening Efficiency DNA Stabilizing Buffer
PRESS RELEASE

published on 07/25/2024 at 14:01, 3 months 26 days ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed launches enhanced ColoAlert test with new features to improve screening efficiency and user experience. The updates aim to optimize colorectal cancer detection

ColoAlert Mainz Biomed Colorectal Cancer Screening Efficiency Enhanced Test
BRIEF

published on 07/09/2024 at 09:06, 4 months 12 days ago

Mainz Biomed Submits for FDA Breakthrough Device Designation for CRC Screening Test

Mainz Biomed Colorectal Cancer FDA Submission Breakthrough Device Screening Test
PRESS RELEASE

published on 07/09/2024 at 09:01, 4 months 12 days ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed N.V. seeks FDA Breakthrough Device Designation for Next Generation CRC Screening Test with impressive clinical results

Mainz Biomed N.V. Colorectal Cancer MRNA Biomarkers FDA Breakthrough Device Designation Next Generation CRC Screening Test
BRIEF

published on 07/02/2024 at 14:06, 4 months 18 days ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Diagnostic Solutions FDA Approval Mainz Biomed Colorectal Cancer Half Year Results
PRESS RELEASE

published on 07/02/2024 at 14:01, 4 months 18 days ago

Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed N.V. provides corporate update for the first half of 2024, showcasing industry-leading clinical data and strategic partnerships. Expect half-year financial results in September 2024

Strategic Partnerships Corporate Update Clinical Data Mainz Biomed N.V. Half-year Financial Results
BRIEF

published on 06/03/2024 at 14:06, 5 months 17 days ago

Mainz Biomed Unveils Industry-Leading Study Results at ASCO 2024

Mainz Biomed MRNA Biomarkers ASCO 2024 CRC Detection Multimodal Screening
PRESS RELEASE

published on 06/03/2024 at 14:01, 5 months 17 days ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed presented industry-leading results of its pooled study at ASCO 2024, demonstrating high sensitivity in detecting colorectal cancer and precancerous lesions using mRNA biomarkers and AI algorithm

Mainz Biomed Colorectal Cancer MRNA Biomarkers ASCO 2024 Precancerous Lesions

Accesswire

Published on 11/21/2024 at 13:30, 20 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 20 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 50 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 50 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 50 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 35 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 15 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 35 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 43 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 50 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 52 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 30 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 5 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 5 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE